Please login to the form below

Not currently logged in
Email:
Password:

Promacta

This page shows the latest Promacta news and features for those working in and with pharma, biotech and healthcare.

FDA clears Dova drug for liver-related low blood platelets

FDA clears Dova drug for liver-related low blood platelets

FDA clears Dova drug for liver-related low blood platelets. Drug is in the same class as Novartis’Promacta/Revolade. ... Doptelet is in the same class as Novartis’ Promacta/Revolade (eltrombopag), originally developed by GlaxoSmithKline, which is

Latest news

  • Novartis’ Promacta receives US breakthrough therapy designation Novartis’ Promacta receives US breakthrough therapy designation

    Novartis’ Promacta receives US breakthrough therapy designation. Regulatory filings of the rare blood disorder treatment are expected this year. ... Regulatory filings for a first-line indication in the US and Europe are expected to be made for Promacta

  • Novartis bags EU approvals for three ex-GSK drugs Novartis bags EU approvals for three ex-GSK drugs

    Revolade - sold as Promacta in the US - has previously been approved to treat the rare disorder chronic immune thrombocytopenia (ITP) in Europe and is also authorised for both ITP and SAA ... Promacta is one of the products from the GSK transaction that

  • Novartis aims to lead immuno-oncology category Novartis aims to lead immuno-oncology category

    The recent acquisition of cancer drugs from GlaxoSmithKline - which included Votrient (pazopanib), Tafinlar (dabrafenib), Mekinist (trametinib) and Promacta (eltrombopag) - added to its portfolio of targeted cancer therapies that can be combined

  • Novartis gets FDA nod for rare blood disorder drug Novartis gets FDA nod for rare blood disorder drug

    Novartis gets FDA nod for rare blood disorder drug. Promacta will provide a treatment option for children over 6 years old. ... The FDA has approved Novartis' Promacta for the treatment of children over six with chronic immune thrombocytopenia (ITP),

  • GSK files Promacta for anaemia indication in US GSK files Promacta for anaemia indication in US

    GSK files Promacta for anaemia indication in US. FDA will review drug under ‘ breakthrough’ designation. ... GSK developed the drug with partners Ligand, which receives royalties on Promacta sales.

More from news
Approximately 6 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Pharma deals during April 2014 Pharma deals during April 2014

    Additional GSK products include the VEGFR inhibitor, Votrient (renal cell carcinoma), Tykerb (HER2 metastatic breast cancer), Arzerra (chronic lymphocytic leukaemia) and Promacta (thrombocytopenia).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics